

1st September, 2020

To,
The General Manager
Department of Corporate Services - CRD
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai 400 001

Dear Sir,

Sub: Outcome of Board Meeting – Quarterly Results

Dear Sir,

Further to our letter dated 24th August, 2020, we would like to inform that the Board of Directors of the Company at its meeting held today ie; 1st September, 2020 at 06.30 P.M and concluded at 8.00 P.M., have approved the Un-Audited Financial Results for the quarter ended 30th June, 2020.

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following:

1. Un-Audited Standalone Financial Results for the quarter ended 30th June, 2020.
2. Un-Audited Consolidated Financial Results for the Quarter ended 30th June, 2020.
3. Auditors' Report on the Standalone and Consolidated Financial Results for the Quarter.


Please Note that the opinion given by the Statutory Auditor in the Enclosed Audit Report is unmodified opinion.

We kindly request you to take the same on record.

Thanking You,
Yours Sincerely,
For **DECIPHER LABS LIMITED**



Kumar Raghavan
**COMPANY SECRETARY &
COMPLIANCE OFFICER**



DECIPHER LABS LIMITED (Formerly known as Combat Drugs Limited) (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor, Plot No.94, Sagar Society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in / www.combatdrugs.in Mail: info@combatdrugs.in / info@decipherlabs.in Ph: 040-48536100

Consolidated UnAudited Financial Results For the Quarter ended 30 June, 2020

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Year ended
	30.06.2020	31.03.2020	30.06.2019	31.03.2020
	Unaudited	Audited	Unaudited	Audited
I. Revenue from operations	1422.17	1759.19	144.29	2398.64
II. Other income	17.46	25.41	0.01	27.29
III.Total revenue (I + II)	1439.63	1784.60	144.30	2425.93
IV. Expenses				
Cost of materials consumed	-	-	-	-
Purchase of Stock-in-Trade	-	-	45.05	61.85
Changes in inventories of finished goods and stock in trade	1.31	-	0.29	0.28
Depreciation and Amortisation	20.19	19.88	0.06	55.61
Employee benefits expense	1297.32	1554.73	60.32	1957.20
Finance costs	37.47	47.86	-	72.15
Other expenses	53.45	60.98	27.65	132.23
Total expenses	1409.74	1683.45	133.37	2279.32
V. Profit/(Loss) before tax (III - IV)	29.89	101.15	10.93	146.61
VI. Tax expense:				
(1) Current tax	10.19	31.31	2.62	40.98
(2) Deferred tax	(0.75)	(0.42)	-	(4.46)
VII. Profit/(Loss) for the period (V-VI)	20.45	70.26	8.31	110.09
VIII. Other comprehensive income				
Items that will be reclassified to statement of profit and loss	-	-	-	-
Exchange differences on translating the financial statements of foreign Subsidiaries	55.21	47.35	0.07	49.65
IX. Total comprehensive income for the year	75.66	117.61	8.38	159.74
Paid Up Equity Share Capital (FV of Rs 10 each)	1010.00	1010.00	800.00	1010.00
X. Earning per equity share				
(1) Basic	0.20	0.07	0.10	0.11
(2) Diluted	0.20	0.07	0.10	0.11

Notes

1) The operations of the Company relate to two segments viz., Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter ended			Year Ended
	30.06.2020	31.03.2020	30.06.2019	31.03.2020
	Unaudited	Audited	Unaudited	Audited
Segment Revenue				
a) Manufacturing and Trading of Pharmaceutical drugs	1.40	14.15	47.10	78.25
b) Consultancy Services	1438.23	1770.45	97.20	2347.68
Total Sales	1439.63	1784.60	144.30	2425.93
Less: Inter Segment Revenue	-	-	-	-
Total Revenue from Operations	1439.63	1784.60	144.30	2425.93
Segment Result (Profit Before Tax and Interest from each Segment)				
a) Manufacturing and Trading of Pharmaceutical drugs	0.06	5.16	1.30	7.06
b) Consultancy Services	67.30	143.86	9.63	211.71
Total	67.36	149.02	10.93	218.77
Less: Interest	37.47	47.86	-	72.15
Total Profit before tax	29.89	101.15	10.93	146.62
Capital employed (Segment assets - segment liabilities)				
Segment assets				

a) Manufacturing and trading of Pharmaceutical drugs	323.32	323.33	280.70	323.33
b) Consultancy Services	2854.61	3214.85	85.92	3214.85
Total Assets	3177.93	3538.18	366.62	3538.18
Segment liabilities				
a) Manufacturing and trading of Pharmaceutical drugs	43.87	45.99	63.95	45.99
b) Consultancy Services	1852.07	2236.12	39.51	2236.12
Total Liabilities	1895.94	2282.11	103.46	2282.11

2) The above results for the Quarter ended 30 June 2020 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 01.09.2020

3) The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act')

read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

4) The COVID-19 outbreak in early 2020 has adversely affected, and may continue to adversely affect economic activity globally, nationally and locally. The management is continuously monitoring the impact of the pandemic on its financial statements. These economic and market conditions and other effects of the COVID-19 outbreak may adversely affect the Company. As of the date of this report, the Group has not faced any material impact to its business. At this point, the extent to which COVID-19 may impact the Group's business is uncertain.

The Management is not aware of any other matter or circumstance, other than those which are disclosed above or not otherwise dealt with in the Financial Statements that has significantly or may significantly affect the operations of the company in the subsequent years the financial effects of which has not been provided for as of the June 30, 2020.

6) The above results include results of wholly owned subsidiaries

i) ICP Solutions Private Limited, India

ii) Decipher Software Solutions LLC, USA

7) The Group has consolidated financial results based on Ind AS 110 "Consolidated Financial Statements".

8) Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.

Place: Hyderabad

Date: 01.09.2020



For and on behalf of the Board

Sushant Mohan Lal

Director

DIN: 01227151

M. ANANDAM & CO.,
CHARTERED ACCOUNTANTS

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the
Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015**

**Review Report to
The Board of Directors
Decipher Labs Limited (Formerly known as Combat Drugs Limited)**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Decipher Labs Limited (Formerly known as Combat Drugs Limited) ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended 30th June, 2020 ("the Statement"), being submitted by the Holding pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following subsidiaries:


Decipher Software Solutions LLC, USA
ICP Solutions Private Limited, India



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the financial results of the subsidiaries referred to in paragraph 6 below nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of one subsidiary, Decipher Software Solutions LLC, USA included in the consolidated unaudited financial results whose interim financial results reflect total revenue of Rs. 1308.67 lakhs, total net profit after tax of Rs. 7.83 lakhs and total comprehensive Income of Rs. 7.83 lakhs for the quarter ended 30th June, 2020, as considered in the consolidated unaudited financial results. These Interim financial results have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosure included in respect of this subsidiary is based solely on the report of such other auditor and the procedures performed by us are as stated in the paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

For M.Anandam & Co.,
Chartered Accountants
(Firm Regn.No.000125S)


Y.Lakshmi Nagarathnam
Partner
Membership Number: 212926



UDIN: 20212926AAAACS2310

Place: Hyderabad
Date: 01.09.2020

DECIPHER LABS LIMITED (FORMERLY KNOWN AS COMBAT DRUGS LIMITED) (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor , Plot No.94,Sagar society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in / www.combatdrugs.in Mail: info@combatdrugs.in / info@decipherlabs.in Ph: 040-48536100

Statement of Standalone Unaudited Financial Results For the Quarter ended 30 June 2020*All amounts in ₹ Lakhs, unless otherwise stated*

Particulars	Quarter ended			Year ended
	30.06.2020	31.03.2020	30.06.2019	31.03.2020
	Unaudited	Audited	Unaudited	Audited
I. Revenue from operations	12.90	14.22	61.06	142.35
II. Other income	0.45	0.38	0.42	1.32
III.Total revenue (I + II)	13.35	14.60	61.48	143.67
IV. Expenses				
Purchase of stock-in-trade	-	-	45.05	61.85
Changes in inventories of stock in trade	1.31	-	0.29	0.28
Employee benefits expense	6.30	8.18	7.88	32.01
Finance costs	0.30	-	-	-
Depreciation expense	0.88	0.17	0.06	0.35
Other expenses	3.02	4.62	5.52	32.43
Total expenses	11.80	12.97	58.80	126.92
V. Profit before tax (III - IV)	1.55	1.63	2.68	16.75
VI. Tax expense:				
(1) Current tax	-	-	-	-
(2) Deferred tax	0.05	(0.03)	-	(0.05)
VII. Profit/(Loss) for the period (V-VI)	1.50	1.66	2.68	16.80
VIII. Other comprehensive income	-	-	-	-
IX. Total comprehensive income for the year	1.50	1.66	2.68	16.80
Paid Up Equity Share Capital (FV of Rs 10 each)	1010.00	1010.00	800.00	1,010.00
X. Earnings per equity share				
(1) Basic	0.01	0.02	0.03	0.17
(2) Diluted	0.01	0.02	0.03	0.17

Notes

- 1) The above results for the quarter ended 30 June 2020 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 1st September, 2020.
- 2) The Company has only one operating segment as per the requirements of Ind AS 108 "Operating Segments".
- 3) Due to the Covid 19 situation, there have been several restrictions imposed by the Governments across the globe considering public health and safety measures during March 2020. Based on the current indicators of economic conditions, the company expects to recover the carrying amount of all its assets. In developing the assumptions relating to the possible future uncertainties in the global economic conditions because of this pandemic, the Company as at date of approval of these financial statements has used Internal and external sources of information including credit reports, related information and economic forecasts. The actual impact of the COVID-19 pandemic may be different from that estimated as at the date of approval of these standalone financial results and the company will continue to closely monitor any material changes to the economic conditions in the future.
- 4) Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.



For and on behalf of the Board

Sushant Mohan Lal
Director
DIN: 01227151

Place: Hyderabad
Date: 01.09.2020

M. ANANDAM & CO.,
CHARTERED ACCOUNTANTS

**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results
of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015**

**Review Report to
The Board of Directors
Decipher Labs Limited (Formerly known as Combat Drugs Limited)**

1. We have reviewed the accompanying statement of Standalone Unaudited Financial Results of Decipher Labs Limited (Formerly known as Combat Drugs Limited) (the Company) for the quarter ended 30th June, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M.Anandam & Co.
Chartered Accountants
(Firm Regn.No.000125S)


Y.Lakshmi Nagaratnam

Partner

Membership Number: 212926

UDIN: 20212926AAAACR9072

Place: Hyderabad

Date: 01.09.2020

